Drug interactions
Baricitinib + Ciltacabtagene autoleucel
Severity: Major
Baricitinib and Ciltacabtagene autoleucel: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Baricitinib may impair CAR T-cell expansion and function and adds to infection risk after lymphodepleting therapy. This may reduce efficacy of the cell product.
What this interaction means in plain words
Baricitinib and Ciltacabtagene autoleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Baricitinib belongs to Musculoskeletal; Ciltacabtagene autoleucel belongs to Miscellaneous.
Why it happens
JAK inhibition suppresses T-cell activation and proliferation, potentially blunting CAR T-cell activity.
What to do
Avoid baricitinib around leukapheresis and CAR T infusion unless essential. Coordinate with the oncology team and monitor for infection.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Baricitinib and Ciltacabtagene autoleucel, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Baricitinib
- Adenovirus types 4 and 7 live + Baricitinib Contraindicated
- Baricitinib + Bcg vaccine live Contraindicated
- Baricitinib + Tofacitinib Contraindicated
- Baricitinib + Upadacitinib Contraindicated
- Abatacept + Baricitinib Major
- Adalimumab + Baricitinib Major
Other interactions of Ciltacabtagene autoleucel
Frequently asked questions
Can I take Baricitinib with Ciltacabtagene autoleucel?
MediHelp rates the interaction as major. Baricitinib and Ciltacabtagene autoleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Baricitinib may impair CAR T-cell expansion and function and adds to infection risk after lymphodepleting therapy. This may reduce efficacy of the cell product.
How serious is the interaction between Baricitinib and Ciltacabtagene autoleucel?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid baricitinib around leukapheresis and CAR T infusion unless essential. Coordinate with the oncology team and monitor for infection.
What other medicines interact with Baricitinib?
MediHelp also lists interactions of Baricitinib with, for example, Adenovirus types 4 and 7 live, Bcg vaccine live, Tofacitinib. The full list is on the Baricitinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
